Deals

Single-asset KaNDy finds $425M exit as Bayer continues to build women’s health portfolio

CEO Kerr sees ‘encouraging’ progress in area where biotechs have struggled to raise money

Bayer adds a menopause program to its women’s health portfolio via a $425M acquisition of KaNDy. Stakeholders say the deal could attract more investment in the space.

Bayer’s $425 million takeout of menopause play KaNDy sends a signal to investors that women’s health can deliver a